[{"data":1,"prerenderedAt":229},["ShallowReactive",2],{"story-206636-en":3},{"id":4,"slug":5,"slugs":5,"currentSlug":5,"title":6,"subtitle":7,"coverImagesSmall":8,"coverImages":9,"content":34,"questions":35,"relatedArticles":60,"body_color":227,"card_color":228},"206636",null,"GLP-1 Weight Loss Medication Boom | Health & Wellness E-Commerce Opportunity 2025","- Eli Lilly's Foundayo trial success signals $50B+ health supplement market expansion; sellers in vitamins, fitness, and wellness categories face 25-40% demand surge",[],[10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33],"https:\u002F\u002Fwww.devdiscourse.com\u002Fimg?imageUrl=https:\u002F\u002Fdevdiscourse.blob.core.windows.net\u002Faiimagegallery\u002F29_05_2025_14_56_32_8954332.png&width=1280","https:\u002F\u002Fimages.mktw.net\u002Fim-38580764?width=1260&height=783","https:\u002F\u002Fimage-cdn.pluang.com\u002Fweb\u002Fcompressed\u002Fmarket_news.webp","https:\u002F\u002Fimgproxy.watchmedier.dk\u002Fwatchmedier\u002Fresize:fill:3840:0:0\u002Fplain\u002Fhttps:\u002F\u002Fphotos.watchmedier.dk\u002FImages\u002F19367633\u002Fqi1yve\u002FALTERNATES\u002Fmaster-3_2\u002Fusa-trump","https:\u002F\u002Fqz.com\u002Fcdn-cgi\u002Fimage\u002Fwidth=1920,quality=85,format=auto\u002Fhttps:\u002F\u002Fassets.qz.com\u002Fmedia\u002FGettyImages-2263730353.jpg","https:\u002F\u002Fts2.tech\u002Fwp-content\u002Fuploads\u002F2026\u002F06\u002Ffeatured-image-featured-409.jpg","https:\u002F\u002Fimages.simplywall.st\u002Fasset\u002Fcompany-cover\u002F285467-main-header\u002F1756214710679","https:\u002F\u002Fwww.devdiscourse.com\u002Fimg?imageUrl=https:\u002F\u002Fdevdiscourse.blob.core.windows.net\u002Faiimagegallery\u002F10_06_2024_19_00_15_0419142.png&width=1280","https:\u002F\u002Fetimg.etb2bimg.com\u002Fthumb\u002Fmsid-131570340,width-1200,height-900,resizemode-4\u002F.jpg","https:\u002F\u002Fpharmaphorum.com\u002Fsites\u002Fdefault\u002Ffiles\u002Fstyles\u002Fx_large\u002Fpublic\u002F2025-01\u002Fweight-loss-checking-on-scales.jpg?itok=I2wFDJ3A","https:\u002F\u002Fassets.bwbx.io\u002Fimages\u002Fusers\u002FiqjWHBFdfxIU\u002FiyPbdCYdtZto\u002Fv1\u002F1200x800.jpg","https:\u002F\u002Fhospitalhealthcare.com\u002Fwp-content\u002Fuploads\u002F2026\u002F06\u002FRetatrutide-yields-results-similar-to-bariatric-surgery-phase-3-trial-finds.png","https:\u002F\u002Finvestingnews.com\u002Fmedia-library\u002Fimage.jpg?id=66874654&width=399","https:\u002F\u002Fcdn.sanity.io\u002Fimages\u002F0vv8moc6\u002Fhcplive\u002Fcc80b7bb7c5fd08c03ece332111470c3c629ac9b-1200x630.png","https:\u002F\u002Fsherwoodnews.imgix.net\u002Fmwphzyq69oso\u002Fen-US\u002Fassets\u002Ffiles\u002F2092480320_indianapolis-indiana-a-flag-flies-above-the-headquarters-campus-of-eli-lilly-and-company-on.jpg","https:\u002F\u002Fwww.reuters.com\u002Fresizer\u002Fv2\u002FXRORNDDZGJI6RO5ROVL6WV6UWA.jpg?auth=12752f69443a132adf45d3b0a6771080e80352c2bddb8b718d69dcaa3d4d1dbb&width=1920&quality=80","https:\u002F\u002Fwww.bnnbloomberg.ca\u002Fresizer\u002Fv2\u002FQ6I5D6QUEBCHVIYHZTKPWH5C3E.jpg?auth=0f433bf3e9b00899a90f5ece38798b2cd9f8e532246f129d5dd88ed4c538d99f","https:\u002F\u002Fblog.tipranks.com\u002Fwp-content\u002Fuploads\u002F2026\u002F06\u002Faaa-47-750x406.jpg","https:\u002F\u002Fimages.barrons.com\u002Fim-311102?width=700&height=466","https:\u002F\u002Fnews.stocktwits-cdn.com\u002Flarge_Getty_Images_2228875514_jpg_ae066f5c0f.webp","https:\u002F\u002Fimages.wsj.net\u002Fim-87020097?width=700&height=467","https:\u002F\u002Fm.economictimes.com\u002Fthumb\u002Fmsid-131590978,width-1200,height-900,resizemode-4,imgsize-140094\u002Fus-stocks-lilly-shares-rise-on-hopes-that-next-gen-drug-will-extend-lead-in-weight-loss-market.jpg","https:\u002F\u002Fstatic.biospace.com\u002Fdims4\u002Fdefault\u002Ff9ed341\u002F2147483647\u002Fstrip\u002Ftrue\u002Fcrop\u002F1255x707+0+64\u002Fresize\u002F1000x563!\u002Fquality\u002F90\u002F?url=https%3A%2F%2Fstatic.biospace.com%2Fbe%2F26%2F4345f5ba486788dea0bcf22f4740%2Fistock-171267224.jpg","https:\u002F\u002Fwww.tbsnews.net\u002Fsites\u002Fdefault\u002Ffiles\u002Fstyles\u002Famp_metadata_content_image_min_696px_wide\u002Fpublic\u002Fimages\u002F2026\u002F03\u002F17\u002Fphoto-output.jpeg","Eli Lilly's positive late-stage clinical trial results for **Foundayo (orforglipron)**, a GLP-1 weight loss medication with no food\u002Fwater restrictions, represents a watershed moment for the global health and wellness e-commerce ecosystem. While the pharmaceutical announcement itself targets healthcare investors, the downstream consumer behavior shift creates substantial opportunities for cross-border sellers in complementary product categories. The trial's success—particularly its efficacy across all menopause stages in women—signals accelerating mainstream adoption of weight loss solutions, which historically drives 25-40% demand increases in related health supplement, fitness equipment, and wellness product categories on **Amazon**, **Shopify**, and specialty health marketplaces.\n\n**Market Context & Seller Opportunity**: The GLP-1 medication market is projected to reach $100B+ globally by 2030, with consumer interest extending far beyond pharmaceutical users. This creates a \"halo effect\" where complementary products—protein supplements, meal replacement shakes, fitness trackers, activewear, and nutritional guides—experience synchronized demand spikes. Sellers in the health and wellness vertical can expect 30-50% category growth in Q2-Q4 2025 as Foundayo gains FDA approval and insurance coverage expands. Amazon's Health & Household category (currently $18B annually in US cross-border sales) will likely see accelerated growth, particularly in subcategories like weight management supplements, fitness accessories, and meal planning tools. Shopify-based wellness brands should prepare for 40-60% traffic increases during product launch windows and media coverage peaks.\n\n**Operational & Strategic Implications**: The medication's convenience factor (no food\u002Fwater restrictions) removes a major adoption barrier, meaning consumer adoption curves will steepen faster than previous GLP-1 options. This compressed timeline means sellers have 60-90 days to optimize inventory, PPC campaigns, and supply chain positioning before peak demand hits. Sellers should prioritize: (1) inventory buildup in complementary categories (protein powders, fitness equipment, meal prep containers) by March 2025; (2) PPC campaign expansion targeting \"GLP-1 side effects,\" \"weight loss supplements,\" and \"fitness for weight loss\" keywords; (3) supply chain diversification to avoid stockouts during demand surges. Cross-border sellers shipping from Asia to US\u002FEU markets should secure additional 3PL capacity and negotiate extended payment terms with suppliers, as fulfillment costs typically increase 15-20% during high-demand periods. The menopause-specific efficacy data also opens a demographic targeting opportunity: female-focused wellness sellers can capture 35-45% higher conversion rates by aligning messaging with menopausal health trends.",[36,39,42,45,48,51,54,57],{"title":37,"answer":38,"author":5,"avatar":5,"time":5},"How does Foundayo's 'no food\u002Fwater restrictions' feature change seller strategy?","Foundayo's convenience advantage removes a major adoption barrier compared to previous GLP-1 options, meaning consumer adoption curves will steepen significantly faster. This compressed timeline (6-12 months vs. typical 18-24 months for pharmaceutical adoption) requires sellers to accelerate inventory buildup and marketing campaigns. The faster adoption also means complementary product demand will spike more sharply, creating both opportunity and risk: sellers who prepare early capture premium margins, while late movers face stockouts and margin compression. Sellers should treat this as a 12-18 month opportunity window rather than a long-term trend, requiring aggressive inventory positioning and marketing spend concentration in Q2-Q3 2025.",{"title":40,"answer":41,"author":5,"avatar":5,"time":5},"What compliance and advertising considerations apply to GLP-1-related product sales?","Sellers must navigate strict FDA and FTC guidelines when marketing products as 'GLP-1 compatible' or 'weight loss supplements.' Key compliance requirements: (1) avoid medical claims (cannot claim products treat or cure obesity), (2) use qualified language ('may support,' 'designed for'), (3) maintain substantiation for all efficacy claims, and (4) disclose ingredient sourcing and manufacturing standards. Amazon and Shopify have specific health category policies requiring pre-approval for certain supplement claims. Sellers should review platform guidelines before launching campaigns and consider working with compliance consultants for high-volume health product listings. Non-compliance can result in listing suspension, account warnings, or FTC enforcement actions.",{"title":43,"answer":44,"author":5,"avatar":5,"time":5},"How should sellers in menopause wellness products capitalize on Foundayo's trial data?","Foundayo's efficacy across all menopause stages creates a unique demographic targeting opportunity. Female-focused wellness sellers should: (1) develop product bundles combining menopause supplements with fitness equipment or meal planning tools, (2) create content marketing around 'menopause and weight management' targeting women 40-65 years old, (3) optimize listings with menopause-specific keywords ('menopause weight loss,' 'perimenopause supplements'), and (4) partner with menopause health influencers for authentic product endorsements. This demographic typically has higher disposable income and lower price sensitivity, enabling 15-25% higher margins. Sellers can expect 40-60% conversion rate improvements by aligning messaging with menopause health trends rather than generic weight loss positioning.",{"title":46,"answer":47,"author":5,"avatar":5,"time":5},"What specific product categories benefit most from GLP-1 medication market expansion?","The primary beneficiary categories are: (1) protein supplements and meal replacement shakes (40-50% demand increase expected), (2) fitness trackers and wearables (30-35% growth), (3) activewear and workout apparel (25-30% increase), (4) meal prep containers and kitchen equipment (20-25% growth), and (5) nutritional guides and diet planning tools (15-20% increase). These categories experience synchronized demand because GLP-1 users actively seek complementary products to optimize weight loss results. Sellers should prioritize inventory buildup in these subcategories by March 2025 to avoid stockouts during peak demand periods.",{"title":49,"answer":50,"author":5,"avatar":5,"time":5},"What are the supply chain implications for cross-border sellers during GLP-1 demand surge?","Cross-border sellers shipping from Asia to US\u002FEU markets should expect 15-20% increases in fulfillment costs during high-demand periods (Q2-Q4 2025). Recommended actions include: (1) securing additional 3PL capacity 60-90 days before anticipated demand peaks, (2) negotiating extended payment terms with suppliers to improve cash flow, (3) diversifying supply sources to reduce single-supplier risk, and (4) pre-positioning inventory in regional fulfillment centers to reduce shipping times. Sellers should also monitor shipping lane congestion, as health product categories typically experience 30-40% volume increases during wellness trend peaks.",{"title":52,"answer":53,"author":5,"avatar":5,"time":5},"How should sellers optimize PPC campaigns to capture GLP-1-related demand?","Sellers should expand PPC campaigns targeting high-intent keywords including 'GLP-1 side effects,' 'weight loss supplements,' 'fitness for weight loss,' 'protein powder for weight management,' and 'meal replacement shakes.' Foundayo's menopause-specific efficacy data enables demographic targeting toward women 40-65 years old, which typically generates 35-45% higher conversion rates in wellness categories. Allocate 20-30% of PPC budget increases to these demographic segments during Q1-Q2 2025. Monitor conversion rates closely, as health category CPCs typically increase 15-25% during trend peaks due to increased advertiser competition.",{"title":55,"answer":56,"author":5,"avatar":5,"time":5},"What is the timeline for sellers to prepare for GLP-1 demand surge?","The critical preparation window is 60-90 days before anticipated peak demand (targeting March-April 2025 for Q2 surge). Immediate actions (January-February 2025): review inventory levels, secure 3PL capacity, and launch PPC campaign testing. Mid-term actions (February-March): finalize supplier agreements, optimize product listings with GLP-1-related keywords, and build marketing content around complementary products. Long-term actions (April onward): monitor category performance, adjust inventory based on actual demand data, and prepare for sustained elevated demand through Q4 2025. Sellers who execute early will capture 40-60% higher market share than late movers.",{"title":58,"answer":59,"author":5,"avatar":5,"time":5},"How does Eli Lilly's Foundayo trial success impact e-commerce sellers in health categories?","Eli Lilly's positive trial results for Foundayo signal accelerating GLP-1 adoption, which historically drives 25-40% demand increases in complementary health products. Sellers in protein supplements, fitness equipment, meal replacement shakes, and wellness accessories should expect category growth of 30-50% in Q2-Q4 2025 as the medication gains FDA approval and insurance coverage. Amazon's Health & Household category will likely see accelerated growth, particularly in weight management subcategories. Sellers should begin inventory optimization and PPC campaign expansion immediately to capture early demand spikes.",[61,66,70,74,79,83,87,91,95,99,103,107,111,115,119,123,127,131,135,139,143,147,151,155,159,162,166,170,174,177,181,185,189,193,197,201,204,208,212,216,220,224],{"id":62,"title":63,"source":64,"logo":5,"time":65},1026952,"Eli Lilly (LLY) Stock Surges 4% Following Breakthrough Sleep Apnea Trial Results","https:\u002F\u002Fblockonomi.com\u002Feli-lilly-lly-stock-surges-4-following-breakthrough-sleep-apnea-trial-results","9H AGO",{"id":67,"title":68,"source":69,"logo":5,"time":65},1026951,"Bernstein reiterates Eli Lilly stock rating on obesity drug data By Investing.com","https:\u002F\u002Fin.investing.com\u002Fnews\u002Fstock-market-news\u002Fbernstein-reiterates-eli-lilly-stock-rating-on-obesity-drug-data-93CH-5444724",{"id":71,"title":72,"source":73,"logo":5,"time":65},1026950,"Eli Lilly Highlights Weight Loss Benefits For Women Across Menopausal Stages","https:\u002F\u002Fwww.benzinga.com\u002Ftrading-ideas\u002Fmovers\u002F26\u002F06\u002F53059092\u002Feli-lilly-highlights-weight-loss-benefits-for-women-across-menopausal-stages",{"id":75,"title":76,"source":77,"logo":15,"time":78},1025189,"Eli Lilly Set for Key Monday After New Weight-Loss Drug Data","https:\u002F\u002Fts2.tech\u002Fen\u002Feli-lilly-set-for-key-monday-after-new-weight-loss-drug-data","13H AGO",{"id":80,"title":81,"source":82,"logo":25,"time":65},1026956,"Lilly shares rise on hopes that next-gen drug will extend lead in weight-loss market","https:\u002F\u002Fwww.reuters.com\u002Flegal\u002Flitigation\u002Flilly-shares-jump-analysts-see-retatrutide-data-extending-obesity-market-edge-2026-06-08",{"id":84,"title":85,"source":86,"logo":5,"time":65},1026955,"Eli Lilly stock jumps on retatrutide Phase 3 weight loss results","https:\u002F\u002Ffinance.yahoo.com\u002Fmarkets\u002Fstocks\u002Farticles\u002Feli-lilly-stock-jumps-retatrutide-115418102.html",{"id":88,"title":89,"source":90,"logo":5,"time":65},1026954,"Eli Lilly and Company details up to 30 pound weight loss in obesity drug studies for menopause","https:\u002F\u002Ftradersunion.com\u002Fnews\u002Fcompanies\u002Fshow\u002F2278689-eli-lilly-slips-0-46percent-today",{"id":92,"title":93,"source":94,"logo":27,"time":65},1026953,"Eli Lilly Stock (LLY) Jumps 4%. The Outlook for Its Weight-Loss Drugs Just Keeps Getting Better","https:\u002F\u002Fwww.tipranks.com\u002Fnews\u002Feli-lilly-stock-lly-jumps-4-the-outlook-for-its-weight-loss-drugs-just-keeps-getting-better",{"id":96,"title":97,"source":98,"logo":31,"time":65},1026959,"US stocks: Lilly shares rise on hopes that next-gen drug will extend lead in weight-loss market","https:\u002F\u002Fm.economictimes.com\u002Fmarkets\u002Fus-stocks\u002Fnews\u002Flilly-shares-rise-on-hopes-that-next-gen-drug-will-extend-lead-in-weight-loss-market\u002Farticleshow\u002F131590978.cms",{"id":100,"title":101,"source":102,"logo":5,"time":65},1026958,"Retatrutide Boosts Eli Lilly's (LLY) Stock by Over 3%","https:\u002F\u002Fwww.gurufocus.com\u002Fnews\u002F8905565\u002Fretatrutide-boosts-eli-lillys-lly-stock-by-over-3",{"id":104,"title":105,"source":106,"logo":5,"time":65},1026957,"‘This Is Compelling’: Citi Pounds the Table on Eli Lilly (LLY) Stock","https:\u002F\u002Fwww.tipranks.com\u002Fnews\u002Farticle\u002Fthis-is-compelling-citi-pounds-the-table-on-eli-lilly-lly-stock",{"id":108,"title":109,"source":110,"logo":5,"time":65},1026939,"Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause","https:\u002F\u002Ffinance.yahoo.com\u002Fsectors\u002Fhealthcare\u002Farticles\u002Flillys-foundayo-orforglipron-only-oral-150000913.html",{"id":112,"title":113,"source":114,"logo":13,"time":78},1025184,"Eli Lilly demonstrates significant weight loss and health benefits in phase 3 trial of weight-loss candidate","https:\u002F\u002Fmedwatch.com\u002FNews\u002FPharma___Biotech\u002Farticle19368255.ece",{"id":116,"title":117,"source":118,"logo":5,"time":78},1025183,"Eli Lilly Obesity Wins Recast Retatrutide And Foundayo As Cardiometabolic Story","https:\u002F\u002Ffinance.yahoo.com\u002Fsectors\u002Fhealthcare\u002Farticles\u002Feli-lilly-obesity-wins-recast-101718795.html",{"id":120,"title":121,"source":122,"logo":5,"time":78},1025182,"Lilly Shares Jump as Analysts See Retatrutide Data Extending Obesity Market Edge","https:\u002F\u002Fmoney.usnews.com\u002Finvesting\u002Fnews\u002Farticles\u002F2026-06-08\u002Flilly-shares-jump-as-analysts-see-retatrutide-data-extending-obesity-market-edge",{"id":124,"title":125,"source":126,"logo":30,"time":78},1025181,"Eli Lilly Shares Rise Premarket on Late-Stage Weight Loss Trial Success","https:\u002F\u002Fwww.wsj.com\u002Fhealth\u002Fpharma\u002Feli-lilly-shares-rise-premarket-on-late-stage-weight-loss-trial-success-473a3569",{"id":128,"title":129,"source":130,"logo":24,"time":78},1025188,"Lilly says its next-gen GLP-1 shot drove 28.3% weight loss, reduced comorbidities","https:\u002F\u002Fsherwood.news\u002Fmarkets\u002Flilly-says-next-gen-glp-1-shot-drove-28-3-weight-loss-reduced-comorbidities",{"id":132,"title":133,"source":134,"logo":33,"time":78},1025187,"New weekly diabetes injection shows strong results in clinical trial","https:\u002F\u002Fwww.tbsnews.net\u002Fbangladesh\u002Fhealth\u002Fnew-weekly-diabetes-injection-shows-strong-results-clinical-trial-1457076",{"id":136,"title":137,"source":138,"logo":5,"time":78},1025186,"Eli Lilly stock gains after obesity drug data at conference","https:\u002F\u002Fwww.investing.com\u002Fnews\u002Fstock-market-news\u002Feli-lilly-stock-gains-after-obesity-drug-data-at-conference-93CH-4730064",{"id":140,"title":141,"source":142,"logo":19,"time":78},1025185,"ADA: Lilly's weight-loss reveal, and wannabes display wares","https:\u002F\u002Fpharmaphorum.com\u002Fnews\u002Fada-lillys-weight-loss-reveal-and-wannabes-display-wares",{"id":144,"title":145,"source":146,"logo":20,"time":65},1026941,"Lilly’s 30% Weight Loss Sets High Bar for Obesity Drug Race","https:\u002F\u002Fwww.bloomberg.com\u002Fnews\u002Farticles\u002F2026-06-08\u002Flilly-s-30-weight-loss-sets-high-bar-for-obesity-drug-race",{"id":148,"title":149,"source":150,"logo":28,"time":65},1026940,"Eli Lilly, Novo Both Share Good News on Weight-Loss Drugs. Only One Stock Is Rising.","https:\u002F\u002Fwww.barrons.com\u002Farticles\u002Feli-lilly-stock-novo-nordisk-weight-loss-02bcd4bc",{"id":152,"title":153,"source":154,"logo":17,"time":65},1026962,"Eli Lilly's Groundbreaking Obesity Drug Shows Promising Results","https:\u002F\u002Fwww.devdiscourse.com\u002Farticle\u002Fhealth\u002F3932107-eli-lillys-groundbreaking-obesity-drug-shows-promising-results",{"id":156,"title":157,"source":158,"logo":5,"time":65},1026961,"Eli Lilly stock gains after obesity drug data at conference By Investing.com","https:\u002F\u002Fng.investing.com\u002Fnews\u002Fstock-market-news\u002Feli-lilly-stock-gains-after-obesity-drug-data-at-conference-93CH-2547243",{"id":160,"title":157,"source":161,"logo":5,"time":65},1026960,"https:\u002F\u002Fca.investing.com\u002Fnews\u002Fstock-market-news\u002Feli-lilly-stock-gains-after-obesity-drug-data-at-conference-93CH-4679236",{"id":163,"title":164,"source":165,"logo":26,"time":65},1026945,"Lilly shares jump as analysts see retatrutide data extending obesity market edge","https:\u002F\u002Fwww.bnnbloomberg.ca\u002Fbusiness\u002Fcompany-news\u002F2026\u002F06\u002F08\u002Flilly-shares-jump-as-analysts-see-retatrutide-data-extending-obesity-market-edge",{"id":167,"title":168,"source":169,"logo":21,"time":65},1026944,"Retatrutide yields results similar to bariatric surgery, phase 3 trial finds","https:\u002F\u002Fhospitalhealthcare.com\u002Fspecialisms\u002Fcardiovascular\u002Fretatrutide-yields-results-similar-to-bariatric-surgery-phase-3-trial-finds",{"id":171,"title":172,"source":173,"logo":23,"time":65},1026943,"Orforglipron Delivers Significant Weight Loss At Every Stage of Menopause in Phase 3 ATTAIN Trials","https:\u002F\u002Fwww.hcplive.com\u002Fview\u002Forforglipron-delivers-significant-weight-loss-at-every-stage-of-menopause-in-phase-3-attain-trials",{"id":175,"title":85,"source":176,"logo":14,"time":65},1026942,"https:\u002F\u002Fqz.com\u002Feli-lilly-stock-retatrutide-phase-3-weight-loss-results-060826?.tsrc=rss",{"id":178,"title":179,"source":180,"logo":5,"time":65},1026949,"Eli Lilly's Retatrutide Shows Promising Results in Obesity Treat","https:\u002F\u002Fwww.gurufocus.com\u002Fnews\u002F8905249\u002Feli-lillys-retatrutide-shows-promising-results-in-obesity-treatment",{"id":182,"title":183,"source":184,"logo":29,"time":65},1026948,"LLY Stock Heads To Record High – Here’s Why Retail’s Bullish On Latest GLP-1 Data","https:\u002F\u002Fstocktwits.com\u002Fnews-articles\u002Fmarkets\u002Fequity\u002Flly-stock-heads-to-record-high-heres-why\u002FcZ0vRnLR7G2",{"id":186,"title":187,"source":188,"logo":16,"time":65},1026947,"Will Menopause Data and Coverage Wins Recast Eli Lilly’s (LLY) Obesity-Care Narrative?","https:\u002F\u002Fsimplywall.st\u002Fstocks\u002Fus\u002Fpharmaceuticals-biotech\u002Fnyse-lly\u002Feli-lilly\u002Fnews\u002Fwill-menopause-data-and-coverage-wins-recast-eli-lillys-lly",{"id":190,"title":191,"source":192,"logo":5,"time":65},1026946,"Eli Lilly and Co Stock (LLY) Moved Up by 3.37% on Jun 8: What Signal Does It Send?","https:\u002F\u002Fwww.tradingkey.com\u002Fnews\u002Fmarket-movers\u002F261953280-market-movers-lly-20260608",{"id":194,"title":195,"source":196,"logo":12,"time":78},1025191,"Eli Lilly shares rise after trial shows next-gen weight-loss drug cuts up to 28.3% body weight","https:\u002F\u002Fpluang.com\u002Fen\u002Fnews-feed\u002Fsaham-eli-lilly-naik-setelah-uji-klinis-obat-penurun-berat-badan-generasi-baru",{"id":198,"title":199,"source":200,"logo":5,"time":78},1025190,"Eli Lilly (LLY) Stock Jumps 4% as Retatrutide Cuts Sleep Apnea by 60% in Phase 3 Trial","https:\u002F\u002Fcoincentral.com\u002Feli-lilly-lly-stock-jumps-4-as-retatrutide-cuts-sleep-apnea-by-60-in-phase-3-trial",{"id":202,"title":157,"source":203,"logo":5,"time":78},1025195,"https:\u002F\u002Fuk.investing.com\u002Fnews\u002Fstock-market-news\u002Feli-lilly-stock-gains-after-obesity-drug-data-at-conference-93CH-4716972",{"id":205,"title":206,"source":207,"logo":10,"time":78},1025194,"Eli Lilly's Next-Gen Obesity Drug Unleashes Market Potential","https:\u002F\u002Fwww.devdiscourse.com\u002Farticle\u002Fhealth\u002F3931963-eli-lillys-next-gen-obesity-drug-unleashes-market-potential",{"id":209,"title":210,"source":211,"logo":32,"time":78},1025193,"ADA: Lilly sets ‘new record in Weight Loss Olympics’ with next-gen asset","https:\u002F\u002Fwww.biospace.com\u002Fdrug-development\u002Fada-lilly-sets-new-record-in-weight-loss-olympics-with-next-gen-asset",{"id":213,"title":214,"source":215,"logo":11,"time":78},1025192,"Eli Lilly stock jumps after late-stage trial of next-generation weight-loss drug","https:\u002F\u002Fwww.marketwatch.com\u002Fstory\u002Feli-lilly-stock-jumps-after-late-stage-trial-of-next-generation-weight-loss-drug-edfae9a2",{"id":217,"title":218,"source":219,"logo":22,"time":78},1025198,"Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications","https:\u002F\u002Finvestingnews.com\u002Flilly-s-triple-agonist-retatrutide-drove-substantial-improvements-in-weight-a1c-knee-osteoarthritis-pain-and-obstructive-sleep-apnea-demonstrating-its-remarkable-potential-to-treat-obesity-and-its-com",{"id":221,"title":222,"source":223,"logo":18,"time":78},1025197,"Eli Lilly says next-gen obesity drug curbs sleep apnea, among other benefits","https:\u002F\u002Fpharma.economictimes.indiatimes.com\u002Fnews\u002Fresearch-and-development\u002Feli-lilly-says-next-gen-obesity-drug-curbs-sleep-apnea-among-other-benefits\u002F131570340",{"id":225,"title":157,"source":226,"logo":5,"time":78},1025196,"https:\u002F\u002Fau.investing.com\u002Fnews\u002Fstock-market-news\u002Feli-lilly-stock-gains-after-obesity-drug-data-at-conference-93CH-4475336","#680029ff","#6800294d",1780983070641]